Rodriguez Arbolí, E., Lee, C. J., Caballero, T., Garcia-Calderon, C., Martinez, C., Bermudez, M. A., … Perez-Simon, J. A. (2022). Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials. In Blood (Vol. 140, pp. 10502–10504). American Society of Hematology. https://doi.org/10.1182/blood-2022-158230

Rodriguez Arbolí, Eduardo, Catherine J. Lee, Teresa Caballero, Clara Garcia-Calderon, Carmen Martinez, Maria Aranzazu Bermudez, Lucía López Corral, et al. “Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials.” In Blood, 140:10502–4. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-158230.

Rodriguez Arbolí E, Lee CJ, Caballero T, Garcia-Calderon C, Martinez C, Bermudez MA, et al. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials. In: Blood. American Society of Hematology; 2022. p. 10502–4.

Rodriguez Arbolí, Eduardo, et al. “Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 10502–04. Crossref, doi:10.1182/blood-2022-158230.

Rodriguez Arbolí E, Lee CJ, Caballero T, Garcia-Calderon C, Martinez C, Bermudez MA, López Corral L, Triguero A, Onstad LE, Sarantopoulos S, Lee SJ, Perez-Simon JA. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials. Blood. American Society of Hematology; 2022. p. 10502–10504.